2,278 results match your criteria Neuro-Oncology[Journal]


Improved neuropsychological outcomes following proton therapy relative to x-ray therapy for pediatric brain tumor patients.

Neuro Oncol 2019 Apr 17. Epub 2019 Apr 17.

Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago IL.

Background: Survivors of pediatric brain tumors are at risk for impaired development in multiple neuropsychological domains. The purpose of this study was to compare neuropsychological outcomes of pediatric brain tumor patients who underwent x-ray radiotherapy (XRT) versus proton radiotherapy (PRT).

Methods: Pediatric patients who underwent either XRT or PRT and received post-treatment age-appropriate neuropsychological evaluation including measures of intelligence (IQ), attention, memory, visuographic skills, academic skills, and parent-reported adaptive functioning were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz070DOI Listing

Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Neuro Oncol 2019 Mar 28. Epub 2019 Mar 28.

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Primary spinal cord tumors represent a hetereogeneous group of central nervous system malignancies whose management is complex given the relatively uncommon nature of the disease and variety of tumor subtypes, functional neurologic deficits from the tumor, and potential morbidities associated with definitive treatment. Advances in neuroimaging; integration of diagnostic, prognostic, and predictive molecular testing into tumor classification; and developments in neurosurgical techniques have refined the current role of radiotherapy in the multimodal management of patients with primary spinal cord tumors, and corroborated the need for prospective, multidisciplinary discussion and treatment decision making. Radiotherapeutic technological advances have dramatically improved the entire continuum from treatment planning to treatment delivery, and the development of stereotactic radiosurgery and proton radiotherapy provides new radiotherapy options for patients treated in the definitive, adjuvant, or salvage setting. Read More

View Article

Download full-text PDF

Source
http://fdslive.oup.com/www.oup.com/pdf/production_in_progres
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz014DOI Listing
March 2019
2 Reads

Association between hippocampal dose and memory in survivors of childhood or adolescent low-grade glioma: a 10-year neurocognitive longitudinal study.

Neuro Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Radiation Oncology, St. Jude Children's Research Hospital.

Background: Hippocampal avoidance has been suggested as a strategy to reduce short-term memory decline in adults receiving whole-brain radiation therapy (RT). The purpose of this study was to determine whether the hippocampal dose in children and adolescents undergoing RT for low-grade glioma (LGG) was associated with memory, as measured by verbal recall.

Methods: Eighty patients aged at least 6 years but less than 21 years with LGG were treated with RT to 54Gy on a phase II protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz068DOI Listing
April 2019
5.562 Impact Factor

Gene therapy with apoptosis-associated speck-like protein (ASC), a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo.

Neuro Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Anesthesiology, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Background: We evaluated Apoptosis-associated speck-like protein (ASC) as a schwannoma tumor suppressor and explored its utilization in a schwannoma gene therapy strategy that may be translated to clinical use.

Methods: ASC protein expression and mRNA level were assessed in human schwannoma by immunohistochemistry and quantitative PCR, respectively. Methylation specific PCR was used to asses ASC promoter methylation. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz065DOI Listing
April 2019
14 Reads
5.562 Impact Factor

Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial.

Neuro Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Background: This report documents the clinical characteristics, molecular grouping and outcome of young children with ependymoma treated prospectively on a clinical trial.

Methods: Fifty-four children (aged ≤ 3 years) with newly diagnosed ependymoma were treated on the SJYC07 trial with maximal safe surgical resection, 4 cycles of systemic chemotherapy, consolidation therapy using focal conformal radiation therapy (RT) (5-mm clinical target volume), and 6 months of oral maintenance chemotherapy. Molecular groups were determined by tumor DNA methylation using Infinium Methylation EPIC BeadChip and profiled on DKFZ/German molecularneuropathology2. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz069DOI Listing
April 2019
1 Read

Prognostic significance of hTERT (human telomerase reverse transcriptase) promoter region mutations C228T and C250T for overall survival in spinal chordomas.

Neuro Oncol 2019 Apr 12. Epub 2019 Apr 12.

Department of Neurosurgery, MD Anderson Cancer Center, The University of Texas, Houston, Texas.

Background: Spinal chordomas, a sub-type of primary spinal column malignancies (PSCM), are rare tumors with poor prognosis and limited understanding of the molecular drivers of neoplasia.

Methods: Study design was a retrospective review of prospectively collected data with cross-sectional survival. Archived paraffin embedded pathologic specimens were collected for 133 patients from 6 centers within Europe and North America between 1987 and 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz066DOI Listing

Foxr2 promotes formation of CNS-embryonal tumors in a Trp53-deficient background.

Neuro Oncol 2019 Apr 12. Epub 2019 Apr 12.

Division of Molecular and Developmental Biology, The Institute of Medical Science, The University of Tokyo, Japan.

Background: Embryonal tumors in the central nervous system (CNS) are primary, aggressive, and poorly differentiated pediatric brain tumors. We identified forkhead box R2 (FOXR2) as an oncogene for medulloblastoma through a transposon-based insertional mutagenesis screen. FOXR2 translocation has been identified in a subset of human embryonal tumors of the CNS, designated as CNS neuroblastoma with FOXR2 activation (CNS NB-FOXR2); however, the in vivo functions of FOXR2 remain elusive. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz067DOI Listing
April 2019
5 Reads

Dose diversification in newly diagnosed GBM.

Neuro Oncol 2019 Apr 8. Epub 2019 Apr 8.

Department of Neurology and Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz063DOI Listing

Global collection of "benign" CNS tumors.

Authors:
Carol Kruchko

Neuro Oncol 2019 Apr 8. Epub 2019 Apr 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz064DOI Listing

REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.

Neuro Oncol 2019 Apr 6. Epub 2019 Apr 6.

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: Glioblastoma (GBM) is a lethal, heterogeneous human brain tumor, with regulatory mechanisms that have yet to be fully characterized. Previous studies have indicated that the transcriptional repressor REST (repressor element-1 silencing transcription factor) regulates the oncogenic potential of GBM stem cells (GSCs) based on level of expression. However, how REST performs its regulatory role is not well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz030DOI Listing
April 2019
2 Reads
5.562 Impact Factor

DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for DIPGs.

Neuro Oncol 2019 Apr 3. Epub 2019 Apr 3.

Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Background: Diffuse intrinsic pontine gliomas (DIPGs) are highly aggressive pediatric brain tumors that are characterized by a recurrent mutation (K27M) within the histone H3 encoding genes H3F3A or HIST1H3A/B/C. These mutations have been shown to induce a global reduction in the repressive histone modification H3K27me3, which together with widespread changes in DNA methylation patterns results in an extensive transcriptional reprogramming hampering the identification of single therapeutic targets based on a molecular rationale.

Methods: We applied a large-scale gene knockdown approach using a pooled shRNA library in combination with next-generation sequencing in order to identify DIPG-specific vulnerabilities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz057DOI Listing
April 2019
1 Read

How to integrate immunotherapy into standard of care in glioblastoma.

Authors:
Michael Platten

Neuro Oncol 2019 Apr 2. Epub 2019 Apr 2.

Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz043DOI Listing

EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.

Neuro Oncol 2019 Mar 29. Epub 2019 Mar 29.

Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. (J.-M.H., M.M., S.M.P., K.W.P. and M.K.).

Background: Posterior fossa A (PFA) ependymomas comprise one out of nine molecular groups of ependymoma. PFA tumors are mainly diagnosed in infants and young children, show a poor prognosis and are characterized by a lack of the repressive histone H3 lysine 27 trimethylation (H3K27me3) mark. Recently, we reported CXorf67 overexpression as hallmark of PFA ependymoma and showed that CXorf67 can interact with EZH2 thereby inhibiting polycomb repressive complex 2 (PRC2), but the mechanism of action remained unclear. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz058DOI Listing
March 2019
6 Reads

Targeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomas.

Neuro Oncol 2019 Mar 28. Epub 2019 Mar 28.

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz052DOI Listing

NG2/CSPG4 in glioblastoma: about flexibility.

Neuro Oncol 2019 Mar 28. Epub 2019 Mar 28.

Unit of Molecular Neuro-Oncology.Fondazione IRCCS Istituto Neurologico Carlo Besta Via Celoria, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz055DOI Listing

Late effects after childhood brain tumour treatment: It's not just about the radiation.

Neuro Oncol 2019 Mar 28. Epub 2019 Mar 28.

Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz054DOI Listing

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Neuro Oncol 2019 03;21(4):424-427

Cleveland Clinic, Cleveland, OH, USA.

Background: The Congress of Neurological Surgeons (CNS) has developed a series of guidelines on the treatment of adults with metastatic brain tumors, including systemic therapy and supportive care topics. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.

Methods: Two CNS Guidelines were reviewed for developmental rigor by methodologists and an independent multi-disciplinary Expert Panel was formed to review the content and assess agreement with the recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422436PMC
March 2019
2 Reads

Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.

Neuro Oncol 2019 Mar;21(4):537-546

Division of Hematology/Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago and Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Background: Gene-mediated cytotoxic immunotherapy (GMCI) is a tumor-specific immune stimulatory strategy implemented through local delivery of aglatimagene besadenovec (AdV-tk) followed by anti-herpetic prodrug. GMCI induces T-cell dependent tumor immunity and synergizes with radiotherapy. Clinical trials in adult malignant gliomas demonstrated safety and potential efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422437PMC
March 2019
1 Read

TERT promoter mutation as a diagnostic marker for diffuse gliomas.

Authors:
Koichi Ichimura

Neuro Oncol 2019 Mar;21(4):417-418

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422426PMC

Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.

Neuro Oncol 2019 Mar 10. Epub 2019 Mar 10.

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, . (MPA, KN, DH, RCC).

Background: Children with diffuse intrinsic pontine glioma (DIPG) succumb to disease within 2 years of diagnosis despite treatment with radiation (IR) and/or chemotherapy. Our aim was to determine the role of PPM1D mutation, present in up to 25% of cases, in DIPG pathogenesis and treatment.

Methods: Using genetic and pharmacologic approaches, we assayed effects of PPM1D mutation on DIPG growth and murine survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz053DOI Listing

A Multi-Institutional Analysis of Presentation and Outcomes for Leptomeningeal Disease Recurrence After Surgical Resection and Radiosurgery for Brain Metastases.

Neuro Oncol 2019 Mar 4. Epub 2019 Mar 4.

Levine Cancer Institute, Atrium Health, Charlotte, NC.

Background: Radiographic leptomeningeal disease (LMD) develops in up to 30% of patients following postoperative stereotactic radiosurgery (SRS) for brain metastases. However, the clinical relevancy of this finding and outcomes after various salvage treatments are not known.

Methods: Patients with brain metastases, of which 1 was resected and treated with adjunctive SRS, and who subsequently developed LMD were combined from 7 tertiary care centers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz049DOI Listing
March 2019
3 Reads

Treatment-Induced Brain Tissue Necrosis: A Clinical Challenge in Neuro-Oncology.

Neuro Oncol 2019 Mar 4. Epub 2019 Mar 4.

MGH Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA, USA.

Cancer therapy-induced adverse effects on the brain are a major challenge in neuro-oncology. Brain tissue necrosis (treatment necrosis; TN) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity. A better understanding of the underlying mechanisms, improvement of diagnostic tools, development of preventive strategies, and implementation of evidence-based therapeutic practices are pivotal to improve patient management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz048DOI Listing
March 2019
5.562 Impact Factor

Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.

Neuro Oncol 2019 Feb 26. Epub 2019 Feb 26.

University of Michigan Medical School, Ann Arbor, MI.

As the field of neuro-oncology makes headway in uncovering the key oncogenic drivers in pediatric glioma, the role of precision diagnostics and therapies continues to rapidly evolve with important implications for the standard of care for clinical management of these patients. Four studies at major academic centers were published in the last year outlining the clinically integrated molecular profiling and targeting of pediatric brain tumors; all four demonstrated the feasibility and utility of incorporating sequencing into the care of children with brain tumors, in particular for children and young adults with glioma. Based on synthesis of the data from these studies and others, we provide consensus recommendations for the integration of precision diagnostics and therapeutics into the practice of pediatric neuro-oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz022DOI Listing
February 2019

The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis.

Neuro Oncol 2019 Feb 23. Epub 2019 Feb 23.

Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Taussig Cancer Institute, Cleveland, OH.

Background: The response of brain metastases (BM) treated with stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICI; PD(L)-1) is of significant interest.

Methods: Patients were divided into cohorts based on ICI sequencing around SRS. The primary outcome was best objective lesion-specific response (BOR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz046DOI Listing
February 2019
2 Reads

Health status, Health-Related Quality of Life and Socio-economic Outcome in Childhood Brain Tumor Survivors: a German Cohort Study.

Neuro Oncol 2019 Feb 22. Epub 2019 Feb 22.

Pediatric Hematology/Oncology, University Children's Hospital Bonn, Germany.

Background: With rising numbers of childhood cancer survivors, somatic and socio-economic outcome as well as the health-related quality of life (QoL) gain increasing relevance. Based on the first nationwide German Survey on Life Situation, State of Health and Quality of Life of Childhood Cancer Survivors, the VIVE-survey, we report the outcome of survivors of childhood brain tumors (BTS) localized in the posterior fossa.

Methods: 270 participants with a median follow-up period of 21. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz044DOI Listing
February 2019
1 Read

Increased Risk of Pseudoprogression among Pediatric Low-Grade Glioma Patients Treated with Proton versus Photon Radiotherapy.

Neuro Oncol 2019 Feb 7. Epub 2019 Feb 7.

Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Background: Pseudoprogression (PsP) is a recognized phenomenon after radiotherapy (RT) for high-grade glioma, but is poorly characterized for low-grade glioma (LGG). We sought to characterize PsP for pediatric LGG patients treated with RT, with particular focus on the role of RT modality using photon-based intensity-modulated RT (IMRT) or proton beam therapy (PBT).

Methods: Serial MRI scans from 83 pediatric LGG patients managed at two institutions between 1998 and 2017 were evaluated. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz042DOI Listing
February 2019
5 Reads

Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning.

Neuro Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Cognitive Neuropsychology, Tilburg University, The Netherlands.

Background: Meningioma patients are known to face cognitive deficits before and after surgery. We examined individual changes in cognitive performance over time and identified preoperative predictors of cognitive functioning 12 months after surgery in a large sample of meningioma patients.

Methods: Patients underwent neuropsychological assessment (NPA) using CNS Vital Signs 1 day before (T0), and 3 (T3) and 12 (T12) months after surgery. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz039DOI Listing
February 2019
46 Reads
5.562 Impact Factor

Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.

Neuro Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Oncology, Clinical Research Unit, Dr Dubois Ferrière Dinu Lipatti Research Foundation, Geneva University Hospital, Geneva, Switzerland.

Background: Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC in HLA-A2 + glioma patients.

Methods: Adult patients with newly diagnosed glioblastoma (n=16) and grade III astrocytoma (n=3) were treated with radiochemotherapy followed by IMA950/poly-ICLC vaccination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz040DOI Listing
February 2019
12 Reads
5.562 Impact Factor

The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients.

Neuro Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Neuropathology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.

Background: SND1 upregulation is a common phenomenon in different human malignant tissues. However, little information is available on the underlying mechanisms through which SND1 affects glioma cell proliferation and invasion.

Methods: SND1, RHOA and MKI67 were analysed in 187 gliomas by immunostaining. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz038DOI Listing
February 2019
7 Reads
5.562 Impact Factor

Prospective, Longitudinal Comparison of Neurocognitive Change in Pediatric Brain Tumor Patients Treated with Proton Radiotherapy versus Surgery Only.

Neuro Oncol 2019 Feb 7. Epub 2019 Feb 7.

Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX.

Background: Proton radiotherapy (PRT) reduces the volume of normal tissue receiving radiation dose, which may lead to better neurocognitive outcomes. We examined change in neurocognitive scores over time in pediatric brain tumor patients treated with proton craniospinal irradiation (CSI), proton focal RT, or surgery only.

Methods: Patients received annual neurocognitive evaluations for up to 6 years. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz041DOI Listing
February 2019
5 Reads

Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus.

Neuro Oncol 2019 Feb 8. Epub 2019 Feb 8.

Center for Neuro-Oncology, Dana-Farber Cancer Institute.

The finding that most grade II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and CDKN2A/B deletional analysis. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz033DOI Listing
February 2019
2 Reads

Septal Dysembryoplastic Neuroepithelial Tumor: A Comprehensive Clinical, Imaging, Histopathologic and Molecular Analysis.

Neuro Oncol 2019 Feb 6. Epub 2019 Feb 6.

Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Background: Dysembryoplastic neuroepithelial tumors (DNETs) are uncommon neural tumors presenting most often in children and young adults and associated with intractable seizures. Rare midline neoplasms with similar histological features to those found in DNETs have been described near the septum pellucidum and termed 'DNET-like neoplasms of the septum pellucidum'. Due to their rarity, these tumors have been described in just a few reports and their genetic alterations sought only in small series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz037DOI Listing
February 2019
6 Reads

Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis.

Neuro Oncol 2019 Feb 6. Epub 2019 Feb 6.

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.

Background: Patients with breast cancer positive for human epidermal growth factor receptor 2 (HER2) remain at high risk of intracranial relapse following treatment and experience increased rates of intracranial failure after stereotactic radiosurgery (SRS). We hypothesized that the addition of concurrent lapatinib to SRS would improve intracranial complete response rates.

Methods: Patients with newly diagnosed HER2-amplified breast cancer brain metastases from 2005-2014 who underwent SRS were included and divided into 2 cohorts based on timing of treatment with lapatinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz006DOI Listing
February 2019
4 Reads

Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.

Neuro Oncol 2019 Feb 6. Epub 2019 Feb 6.

Center for Magnetic Resonance Research and Department of Radiology, University of Minnesota, Minneapolis, MN, USA.

Background: Codeletion of chromosome arms 1p and 19q (1p/19q codeletion) highly benefit diagnosis and prognosis in gliomas. In this study, we investigated the effect of 1p/19q codeletion on cancer-cell metabolism and evaluated possible metabolic targets for tailored therapies.

Methods: We combined in vivo 1H magnetic resonance spectroscopy (MRS) measurements in human gliomas with the analysis of a series of standard amino acids by liquid chromatography-mass spectroscopy (LC-MS) in human glioma biopsies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz031DOI Listing
February 2019
3 Reads

Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas.

Neuro Oncol 2019 Feb 5. Epub 2019 Feb 5.

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA.

Background: Neurofibromatosis type 1 (NF1) is a tumor-predisposition disorder caused by germline mutations in NF1. NF1 patients have an 8-16% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST), a highly-aggressive soft-tissue sarcoma, often arising from pre-existing benign plexiform neurofibromas (PN) and atypical neurofibromas (ANF). ANF are distinct from both PN and MPNST, representing an intermediate step in malignant transformation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz028DOI Listing
February 2019
9 Reads

TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma.

Neuro Oncol 2019 Feb 5. Epub 2019 Feb 5.

UMR 1023, IMIV, Service Hospitalier Frédéric Joliot, CEA, Inserm, Univsité Paris Sud, CNRS, Université Paris-Saclay, Orsay, France.

Background: Glioblastoma is the most devastating brain tumor. Despite the use of multimodal treatments, most patients relapse, often due to the highly invasive nature of gliomas. However, the detection of glioma infiltration remains challenging. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz029DOI Listing
February 2019
12 Reads

A Low Percentage of Metastases in Deep Brain and Temporal Lobe Structures.

Neuro Oncol 2019 Jan 23. Epub 2019 Jan 23.

Department of Radiology Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA.

Background: Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized BMs are not evenly distributed across the brain and that several additional areas may be avoided in WBRT based on a low risk of developing a BM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz023DOI Listing
January 2019
1 Read

The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility, and a revised proposal.

Neuro Oncol 2019 01 23. Epub 2019 Jan 23.

Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.

Background: A scorecard to evaluate magnetic resonance imaging (MRI) findings during the course of leptomeningeal metastases (LM) has been proposed by the Response Assessment in Neuro-Oncology (RANO) group.

Methods: To explore the feasibility of the LANO scorecard, cerebrospinal MRI of 22 patients with LM from solid tumors were scored by 10 neuro-oncologists and 9 neuroradiologists at baseline and at follow-up after treatment. Raters were blinded for clinical data including treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz024DOI Listing
January 2019
2 Reads
5.562 Impact Factor

Identification of genes functionally involved in the detrimental effects of mutant histone H3.3-K27M in Drosophila melanogaster.

Neuro Oncol 2019 Jan 23. Epub 2019 Jan 23.

Institute of Neuropathology, University Hospital Münster, Münster, Germany.

Background: Recurrent specific mutations in evolutionarily conserved Histone 3 (H3) variants drive pediatric high-grade gliomas (HGG), but little is known about their downstream effects. The aim of this study was to identify genes involved in the detrimental effects of mutant H3.3-K27M, the main genetic driver in lethal midline HGG, in a transgenic Drosophila model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz021DOI Listing
January 2019

Diet and risk of glioma: combined analysis of three large prospective studies in the UK and USA.

Neuro Oncol 2019 Jan 23. Epub 2019 Jan 23.

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford.

Background: Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimise possible differential dietary recall between those with and without glioma, we present findings from three large prospective studies.

Methods: Participants included 692,176 from (UK) Million Women Study, 470,780 from (US) NIH-AARP Study, and 99,148 from (US) PLCO Study. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz013DOI Listing
January 2019
1 Read

Corrigendum.

Authors:

Neuro Oncol 2019 Jan 28. Epub 2019 Jan 28.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy203DOI Listing
January 2019

Accelerated progression of IDH mutant glioma after first recurrence.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Translational Neuro-Oncology Laboratory, Massachusetts General Hospital.

Background: Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct subtype, reflected in WHO 2016 revised diagnostic criteria. To inform IDH-targeting trial design, we sought to characterize outcomes exclusively within IDH mutant gliomas.

Methods: We retrospectively analyzed 275 IDH mutant glioma patients treated at our institution. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz016DOI Listing
January 2019
11 Reads

Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-Based Classification.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Background: A feature of glioblastoma (GBM) is cellular and molecular heterogeneity, both within and between tumors. This variability causes a risk for sampling bias and potential tumor escape from future targeted therapy. Heterogeneous intra-tumor gene expression in GBM is well documented, but little is known regarding the epigenetic heterogeneity. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz011DOI Listing
January 2019
9 Reads

Liquid biopsy in Central Nervous System metastases: a RANO review and proposals for clinical applications.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy.

Liquid biopsies collect and analyze tumor components in body fluids, and there is an increasing interest in the investigation of liquid biopsies as a surrogate for tumor tissue in the management of both primary and secondary brain tumors. Herein we critically review available literature on spinal fluid and plasma circulating tumor cells (CTCs) and cell-free tumor (ctDNA) for diagnosis and monitoring of leptomeningeal and parenchymal brain metastases. We discuss technical issues and propose several potential applications of liquid biopsies in different clinical settings, i. Read More

View Article

Download full-text PDF

Source
http://fdslive.oup.com/www.oup.com/pdf/production_in_progres
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz012DOI Listing
January 2019
10 Reads

Modulation of temozolomide dose differentially affects T cell response to immune checkpoint inhibition.

Neuro Oncol 2019 Jan 22. Epub 2019 Jan 22.

Preston A. Wells Jr. Center for Brain Tumor Therapy UF Brain Tumor Immunotherapy Program Lillian S. Wells Department of Neurosurgery University of Florida Gainesville, FL.

Background: The changes induced in host immunity and the tumor microenvironment by chemotherapy have been shown to impact immunotherapy response in both a positive and negative fashion. Temozolomide is the most common chemotherapy used to treat glioblastoma (GBM) and has been shown to have variable effects on immune response to immunotherapy. Therefore, we aimed to determine the immune modulatory effects of temozolomide that would impact response to immune checkpoint inhibition in the treatment of experimental GBM. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/advance-article/doi/
Publisher Site
http://dx.doi.org/10.1093/neuonc/noz015DOI Listing
January 2019
5 Reads

Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging.

Neuro Oncol 2019 Mar;21(4):527-536

Department of Diagnostic Radiology, UT MDACC, Houston, Texas.

Background: Undersampling of gliomas at first biopsy is a major clinical problem, as accurate grading determines all subsequent treatment. We submit a technological solution to reduce the problem of undersampling by estimating a marker of tumor proliferation (Ki-67) using MR imaging data as inputs, against a stereotactic histopathology gold standard.

Methods: MR imaging was performed with anatomic, diffusion, permeability, and perfusion sequences, in untreated glioma patients in a prospective clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422438PMC
March 2019
5 Reads

Brain and central nervous system tumor statistics: access to accurate data for all countries is critical!

Neuro Oncol 2019 Jan 14. Epub 2019 Jan 14.

Case Comprehensive Cancer Center and Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noy205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380403PMC
January 2019
1 Read

Imaging and diagnostic advances for intracranial meningiomas.

Neuro Oncol 2019 Jan;21(Supplement_1):i44-i61

Center for Skull Base and Pituitary Surgery, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

The archetypal imaging characteristics of meningiomas are among the most stereotypic of all central nervous system (CNS) tumors. In the era of plain film and ventriculography, imaging was only performed if a mass was suspected, and their results were more suggestive than definitive. Following more than a century of technological development, we can now rely on imaging to non-invasively diagnose meningioma with great confidence and precisely delineate the locations of these tumors relative to their surrounding structures to inform treatment planning. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article/21/Supplemen
Publisher Site
http://dx.doi.org/10.1093/neuonc/noy143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347083PMC
January 2019
13 Reads